Notes
The study was funded by Sanofi, China.
Reference
Xuan D, et al. A Cost-Effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-Fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China. Clinical Therapeutics : 20 Sep 2018. Available from: URL: http://doi.org/10.1016/j.clinthera.2018.08.017
Rights and permissions
About this article
Cite this article
Rabbit antithymocyte globulin better choice in renal transplant. PharmacoEcon Outcomes News 813, 25 (2018). https://doi.org/10.1007/s40274-018-5332-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5332-1